A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
IMpower150
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
2 other identifiers
interventional
1,202
25 countries
224
Brief Summary
This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve participants with Stage IV non-squamous NSCLC. Participants were randomized in a 1:1:1 ratio to Arm A (Atezolizumab+Carboplatin+Paclitaxel), Arm B (Atezolizumab+Carboplatin+Paclitaxel+Bevacizumab), or Arm C (Carboplatin+Paclitaxel+Bevacizumab).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Mar 2015
Longer than P75 for phase_3
224 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 12, 2015
CompletedFirst Posted
Study publicly available on registry
February 19, 2015
CompletedStudy Start
First participant enrolled
March 31, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 13, 2019
CompletedResults Posted
Study results publicly available
October 27, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 7, 2020
CompletedSeptember 23, 2021
August 1, 2021
4.5 years
February 12, 2015
August 21, 2020
August 26, 2021
Conditions
Outcome Measures
Primary Outcomes (3)
Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population
Progression Free Survival (PFS), as Determined by the Investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Arm B versus Arm C in the T-effector (Teff)-high wild type (WT) population and the intent-to-treat (ITT)-WT population.
Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)
Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population
Overall Survival (OS) in Arm B Versus Arm C in ITT-WT Population
Baseline until death until data cut-off on 22 January 2018 (up to approximately 34 months)
Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population
Overall Survival (OS) in Arm A Versus Arm C in ITT-WT Population
Baseline until death (up approximately 53 months)
Secondary Outcomes (24)
PFS, as Determined by the Independent Review Facility (IRF) in Arm B Versus Arm C in Teff-High-WT Population and ITT-WT Population
Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)
PFS, as Determined by the Investigator in Arm B Versus Arm C in Teff High Population and ITT Population
Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)
PFS, as Determined by the Investigator in Arm A Versus Arm B in Teff High-WT Population and ITT-WT Population
Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)
PFS, as Determined by the Investigator in Arm B Versus Arm C by PD-L1 Subgroup
Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)
OS in Arm B Versus Arm C by PD-L1 Subgroup
Baseline until death (up to approximately 34 months)
- +19 more secondary outcomes
Study Arms (3)
Arm A (Atezolizumab+Paclitaxel+Carboplatin)
EXPERIMENTALParticipants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)
EXPERIMENTALParticipants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
Arm C (Bevacizumab+Paclitaxel+Carboplatin)
ACTIVE COMPARATORParticipants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
Interventions
Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.
Bevacizumab was administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.
Carboplatin was administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
Paclitaxel was administered as IV infusion at a dose of 200 milligrams per square meter (mg/m\^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
Eligibility Criteria
You may qualify if:
- Eastern Cooperative Oncology Group performance status 0 or 1
- Histologically or cytologically confirmed, Stage IV non-squamous NSCLC
- Participants with no prior treatment for Stage IV non-squamous NSCLC
- Known PD-L1 status as determined by immunohistochemistry assay performed on previously obtained archival tumor tissue or tissue obtained from a biopsy at screening
- Measurable disease as defined by RECIST v1.1
- Adequate hematologic and end organ function
You may not qualify if:
- Active or untreated central nervous system metastases
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
- Pregnant or lactating women
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
- Positive test for human immunodeficiency virus
- Active hepatitis B or hepatitis C
- Severe infection within 4 weeks prior to randomization
- Significant cardiovascular disease
- Illness or condition that interferes with the participant's capacity to understand, follow and/or comply with study procedures
- Prior treatment with cluster of differentiation 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1, and anti-PD-L1 therapeutic antibodies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (240)
Ironwood Cancer & Research Centers
Chandler, Arizona, 85224, United States
Arizona Oncology Associates
Flagstaff, Arizona, 86001, United States
Southern CA Permanente Med Grp
Bellflower, California, United States
Marin Cancer Care Inc
Greenbrae, California, 94904, United States
Scripps Health
La Jolla, California, 92037, United States
Chao Family Comprehensive Cancer Center UCI
Orange, California, 92868, United States
Rocky Mountain Cancer Center
Denver, Colorado, 80218, United States
Kaiser Permanente
Lonetree, Colorado, 80124, United States
Danbury Hospital
Danbury, Connecticut, 06810, United States
Yale Cancer Center
New Haven, Connecticut, 06520, United States
Holy Cross Hospital Inc
Fort Lauderdale, Florida, 33308, United States
Cancer Specialists of North Florida - Baptist South
Jacksonville, Florida, 32258, United States
Mount Sinai Medical Center
Miami Beach, Florida, 33140, United States
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, 34952, United States
Piedmont Cancer Institute, PC
Atlanta, Georgia, 30318, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
Univ of Chicago
Chicago, Illinois, 60637, United States
Ingalls Memorial Hospital
Harvey, Illinois, 60426, United States
Oncology Specialists, S.C.
Park Ridge, Illinois, 60068, United States
Hematology-Oncology; Associates of the Quad Cities
Bettendorf, Iowa, 52722, United States
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
New England Cancer Specialists
Scarborough, Maine, 04074, United States
Mercy Medical Center
Baltimore, Maryland, 21202, United States
Regional Cancer Care Associates
Bethesda, Maryland, 20817, United States
Maryland Oncology Hematology, P.A.
Columbia, Maryland, 21044, United States
St. Joseph Mercy Health System
Ann Arbor, Michigan, 48106, United States
St. Luke's Regional Cancer Center
Duluth, Minnesota, 55805, United States
Park Nicolett - Frauenshuh Cancer Center
Saint Louis Park, Minnesota, 55426, United States
St. Luke's Cancer Institute
Kansas City, Missouri, 64111, United States
Missouri Baptist Medical Center
St Louis, Missouri, 63131, United States
Billings Clinic
Billings, Montana, 59102, United States
Montana Cancer Specialists
Missoula, Montana, 59802, United States
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, 89014, United States
Summit Medical Group
Berkeley Heights, New Jersey, 07922, United States
Valley Hospital; Oncology Research
Paramus, New Jersey, 07652, United States
Regional Cancer Care Associates LLC
Sewell, New Jersey, 08080, United States
Maimonides Medical Center
Brooklyn, New York, 11219, United States
Montefiore Medical Center
The Bronx, New York, 10467, United States
First Health of the Carolinas
Pinehurst, North Carolina, 28374, United States
University of Cincinnati
Cincinnati, Ohio, 45203-0542, United States
Mercy St Anne Hospital
Toledo, Ohio, 43623, United States
Bend Memorial Clinic
Bend, Oregon, 97701, United States
St. Charles Medical Center Bend; Cancer Care Of The Cascades
Bend, Oregon, 97701, United States
Willamette Valley Cancer Insitute and Research Center
Springfield, Oregon, 97477, United States
St. Luke's Cancer Care Associates
Bethlehem, Pennsylvania, 18015, United States
Allegheny Cancer Center
Pittsburgh, Pennsylvania, 15212, United States
Univ of Pittsburgh Medical Ctr
Pittsburgh, Pennsylvania, 15232, United States
West Clinic
Germantown, Tennessee, 38138, United States
Tennessee Cancer Specialists
Knoxville, Tennessee, 37920, United States
Houston Methodist Cancer Center
Houston, Texas, 77030, United States
Longview Cancer Center
Longview, Texas, 75601, United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229, United States
Virginia Cancer Specialists, PC
Fairfax, Virginia, 22031, United States
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
Virginia Cancer Institute
Richmond, Virginia, 23226, United States
Blue Ridge Cancer Care
Roanoke, Virginia, 24014, United States
MultiCare Regional Cancer Center - Auburn
Auburn, Washington, 98002-4117, United States
Providence Regional Cancer Partnership
Everett, Washington, 98201, United States
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
Medical Oncology Associates
Spokane, Washington, 99208, United States
West Virginia University; Mary Babb Randolph Can Ctr
Morgantown, West Virginia, 26506, United States
Centro Medico Austral
Buenos Aires, 1019, Argentina
Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, C1125ABD, Argentina
Sanatorio Allende
Córdoba, X5000JHQ, Argentina
Centro Oncologico Riojano Integral (CORI)
La Rioja, F5300COE, Argentina
Hospital Provincial del Centenario
Rosario, 2000, Argentina
Fundacion Koriza
Santa Rosa, 6300, Argentina
Centro de Investigacion; Clinica - Clinica Viedma S.A.
Viedma, R8500ACE, Argentina
Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050, Australia
Concord Repatriation General Hospital
Concord, New South Wales, 2139, Australia
Nepean Cancer Care Centre
Sydney, New South Wales, 2747, Australia
Prince Charles Hospital; Department of Medical Oncology
Chermside, Queensland, 4032, Australia
Townsville Hospital
Townsville, Queensland, 4810, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
Adelaide Cancer Centre
Kurralta Park, South Australia, 5037, Australia
Royal Hobart Hospital
Hobart, Tasmania, 7000, Australia
Launceston General Hospital
Launceston, Tasmania, 7250, Australia
Frankston Hospital
Frankston, Victoria, 3199, Australia
Austin Health
Heidelberg, Victoria, 3084, Australia
Cabrini Hospital Malvern
Malvern, Victoria, 3144, Australia
The Alfred Hospital
Prahan, Victoria, 3181, Australia
Sunshine Hospital
St Albans, Victoria, 3021, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, 6009, Australia
Paracelsus Medizinische Privatuniversität
Salzburg, 5020, Austria
Klinikum Wels-Grieskirchen
Wels, 4600, Austria
CHU de Liège
Liège, 4000, Belgium
Clinique Ste-Elisabeth
Namur, 5000, Belgium
CETUS Hospital Dia Oncologia
Uberaba, Minas Gerais, 38082-049, Brazil
Instituto Do Cancer Delondrina_X; Unidade De Pesquisa Clinica
Londrina, Paraná, 86 015 520, Brazil
Liga Norte Riograndense Contra O Câncer
Natal, Rio Grande do Norte, 59040150, Brazil
IPCEM; Instituto de Pesquisa de Estudos Multicêntricos
Caxias do Sul, Rio Grande do Sul, 95070-560, Brazil
Hospital Mae de Deus
Porto Alegre, Rio Grande do Sul, 90470-340, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, 14784-400, Brazil
Instituto Ribeirãopretano de Combate Ao Câncer; Centro Especializado De Oncologia
Ribeirão Preto, São Paulo, 14015-130, Brazil
Hospital de Base de Sao Jose do Rio Preto
São José do Rio Preto, São Paulo, 15090-000, Brazil
Hospital A. C. Camargo; Oncologia
São Paulo, São Paulo, 01509-010, Brazil
Multiprofile Hospital for Active Treatment Central Onco Hospital OOD
Plovdiv, 4000, Bulgaria
MHAT Serdika, EOOD
Sofia, 1303, Bulgaria
Lakeridge Health Center
Oshawa, Ontario, L1J 2J2, Canada
Clinica Santa Maria
Santiago, 0, Chile
Health & Care SPA
Santiago, 7500006, Chile
Sociedad de Investigaciones Medicas Ltda (SIM)
Temuco, 4810469, Chile
Institut Bergonié Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest
Bordeaux, 33076, France
CHU de Grenoble
Grenoble, 38043, France
Centre Jean Bernard Clinique Victor Hugo
Le Mans, 72015, France
Hôpital Saint Joseph
Marseille, 13008, France
Hopital Nord AP-HM
Marseille, 13015, France
Hôpital Européen Georges Pompidou
Paris, 75908, France
CHU de Bordeaux
Pessac, 33600, France
Service de Pneumologie Centre Hospitalier Régional La Réunion Site Felix Guyon
Saint-Denis, 97405, France
CH de Saint Quentin
Saint-Quentin, 2100, France
Centre Hospitalier Intercommunal Toulon - La Seyne sur Mer
Toulon, 83000, France
Hôpital d'Instruction des Armées de Sainte Anne; Service de Pneumologie
Toulon, 83000, France
Hôpital Larrey;Université Paul Sabatier
Toulouse, 31059, France
Zentralklinikum Augsburg
Augsburg, 86156, Germany
Helios Klinikum Emil von Behring GmbH
Berlin, 14165, Germany
Ev.Krankenhaus Bielefeld gGmbH; Klinik für Innere Medizin und Geriatrie
Bielefeld, 33611, Germany
Augusta Kranken-Anstalt gGmbH
Bochum, 44791, Germany
Kliniken der Stadt Koln gGmbH; Lungenklinik Onkologische Ambulanz
Cologne, 51109, Germany
Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
Dresden, 01307, Germany
St. Elisabethen Krankenhaus
Frankfurt am Main, 60487, Germany
LungenClinic Großhansdorf GmbH
Großhansdorf, 22927, Germany
Krankenhaus Martha-Maria; Halle-Dolau gGmbH
Halle, 06120, Germany
Asklepios Klinik Harburg
Hamburg, 21075, Germany
Lungenklinik Hemer
Hemer, 58675, Germany
Universität Des Saarlandes; Klinik für Innere Medizin V
Homburg, 66421, Germany
Klinik Loewenstein gGmbH; Onk & Pal
Löwenstein, 74245, Germany
Klinikum Bogenhausen
München, 81925, Germany
Krankenhaus Barmherzige Bruder Regensburg
Regensburg, 93049, Germany
Klinikum der Universität Regensburg
Regensburg, 93053, Germany
Stiftung Mathias-Spital Rheine
Rheine, 48431, Germany
AORN A Cardarelli
Napoli, Campania, 80131, Italy
Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica
Rome, Lazio, 00128, Italy
Azienda Ospedaliera San Camillo Forlanini
Rome, Lazio, 00152, Italy
Università Cattolica Del S Cuore
Rome, Lazio, 00168, Italy
Istituto Nazionale per la Ricerca sul Cancro di Genova
Genoa, Liguria, 16132, Italy
ASL 3 Genovese; DSM
Genoa, Liguria, 16147, Italy
A.O.U. Maggiore della Carità
Novara, Piedmont, 28100, Italy
Azienda Unita Sanitaria Locale N1 Sassari; Unita Operativa Di Oncologia Medica
Sassari, Sardinia, 07100, Italy
Policlinico Vittorio Emanuele
Catania, Sicily, 95123, Italy
Ospedale Versilia
Lido di Camaiore, Tuscany, 55043, Italy
Ospedale Civile - Livorno
Livorno, Tuscany, 57124, Italy
National Hospital Organization Shikoku Cancer Center
Ehime, 791-0280, Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, 810-8563, Japan
NHO Kyushu Cancer Center
Fukuoka, 811-1395, Japan
Kurume University Hospital
Fukuoka, 830-0011, Japan
Kanagawa Cardiovascular and Respiratory Center
Kanagawa, 236-0051, Japan
Kitasato University Hospital
Kanagawa, 252-0375, Japan
Kyoto University Hospital
Kyoto, 606-8507, Japan
Miyagi Cancer Center
Miyagi, 981-1293, Japan
Niigata Cancer Center Hospital
Niigata, 951-8566, Japan
Osaka City University Hospital
Osaka, 545-8586, Japan
National Hospital Organization Osaka Toneyama Medical Center
Osaka, 560-8552, Japan
Toranomon Hospital
Tokyo, 105-8470, Japan
Center Hospital of the National Center for Global Health and Medicine
Tokyo, 162-0052, Japan
Kyorin University Hospital
Tokyo, 181-8611, Japan
Wakayama Medical University Hospital
Wakayama, 641-8510, Japan
Pauls Stradins Clinical University Hospital
Riga, LV-1002, Latvia
Riga East Clinical University Hospital Latvian Oncology Centre
Riga, LV-1079, Latvia
National Cancer Institute
Vilnius, 08660, Lithuania
Centro Universitario Contra El Cancer
Monterrey, 64020, Mexico
Cancerologia de Queretaro
Querétaro, 76090, Mexico
Centro Hemato Oncologico Privado; Oncologia
Toluca, 50080, Mexico
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, 5223 GZ, Netherlands
Amsterdam UMC Location VUMC
Amsterdam, 1081 HV, Netherlands
Amphia Ziekenhuis; Afdeling Longziekten
Breda, 4818 CK, Netherlands
Ziekenhuis Gelderse Vallei
Ede, 6716 RP, Netherlands
Tergooiziekenhuizen
Hilversum, 1201 DA, Netherlands
Spaarne Gasthuis; Spaarne Ziekenhuis
Hoofddorp, 2134 TM, Netherlands
Maastricht University Medical Center
Maastricht, 6229 HX, Netherlands
St. Antonius Ziekenhuis; R&D Long
Nieuwegein, 3435 CM, Netherlands
Erasmus MC; Afdeling Longziekten
Rotterdam, 3015 GD, Netherlands
Maasstad ziekenhuis
Rotterdam, 3079 DZ, Netherlands
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
Gelre Ziekenhuizen, Zutphen
Zutphen, 7207 AE, Netherlands
Centro Medico Monte Carmelo
Arequipa, 04001, Peru
Centro Especializado de Enfermedades Neoplásicas
Arequipa, Peru
Instituto Nacional de Enfermedades Neoplasicas
Lima, Lima 34, Peru
Centro Hospitalar E Universitário de Coimbra EPE
Coimbra, 3000-602, Portugal
Instituto Portugues Oncologia de Lisboa Francisco Gentil EPE
Lisbon, 1099-023, Portugal
Hospital Pulido Valente; Servico de Pneumologia
Lisbon, 1796-001, Portugal
Centro Hospitalar do Porto - Hospital de Santo António
Porto, 4099-001, Portugal
Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe
Porto, 4200-072, Portugal
Hospital de Sao Joao; Servico de Pneumologia
Porto, 4200, Portugal
Moscow City Oncology Hospital #62
Moscovskaya Oblast, Moscow Oblast, 143423, Russia
Russian Oncology Research Center n.a. N.N. Blokhin
Moscow, 115478, Russia
Clinical Oncology Dispensary
Omsk, 644013, Russia
Evromedservis LCC
Pushkin, 196603, Russia
City Clinical Oncology Dispensary
Saint Petersburg, 197022, Russia
National Cancer Centre; Medical Oncology
Singapore, 169610, Singapore
Univerzitna nemocnica Bratislava
Bratislava, 813 69, Slovakia
Narodny onkologicky ustav
Bratislava, 833 10, Slovakia
POKO Poprad s.r.o.
Poprad, 058 01, Slovakia
Hospital Universitario Son Espases
Palma de Mallorca, Balearic Islands, 07014, Spain
Instituto Catalan de Oncologia de Hospitalet (ICO); Servicio de Farmacia
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
Sabadell, Barcelona, 8208, Spain
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008, Spain
Hospital Universitario Insular de Gran Canaria
Las Palmas de Gran Canaria, LAS Palmas, 35016, Spain
Complejo Hospitalario U. de Ourense
Ourense, Orense, 32005, Spain
Hospital Lluis Alcanyis De Xativa
Xàtiva, Valencia, 46800, Spain
Hospital del Mar
Barcelona, 08003, Spain
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Barcelona, 08035, Spain
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
Hospital Universitario Reina Sofia
Córdoba, 14004, Spain
Hospital Lucus Augusti; Servicio de Oncologia
Lugo, 27003, Spain
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
Madrid, 28007, Spain
Hospital Universitario La Paz
Madrid, 280146, Spain
Hospital Ramon y Cajal; Servicio de Oncologia
Madrid, 28034, Spain
Hospital Clinico San Carlos; Servicio de Oncologia
Madrid, 28040, Spain
Hospital Universitario Fundación Jimenez Díaz
Madrid, 28040, Spain
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Hospital Universitario HM Sanchinarro-CIOCC
Madrid, 28050, Spain
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
Kantonsspital Baselland
Bruderholz, 4101, Switzerland
Luzerner Kantonsspital Sursee
Lucerne, 6000, Switzerland
Kantonsspital St. Gallen; Onkologie/Hämatologie
Sankt Gallen, 9007, Switzerland
Changhua Christian Hospital; Hematology-Oncology
Changhua, 500, Taiwan
Kaohsiung Medical University Hospital; Department of Urology
Kaohsiung City, 807, Taiwan
Chi Mei Medical Center Liou Ying Campus
Liuying Township, 736, Taiwan
Chang Gung Memorial Hospital Chiayi
Putzu, 613, Taiwan
National Cheng Kung Univ Hosp
Tainan, 00704, Taiwan
National Taiwan Uni Hospital
Taipei, 10041, Taiwan
Cheng Hsin General Hospital
Taipei, 112, Taiwan
Tri-Service General Hospital
Taipei, 11490, Taiwan
Chang Gung Medical Foundation Linkou Branch
Taoyuan, 333, Taiwan
Taichung Veterans General Hospital
Xitun Dist., 40705, Taiwan
ME Bukovinian Clinical Oncology Center
Chernivtsi, Chernihiv Governorate, 58013, Ukraine
Municipal Institution City Clinical Hospital #4 of Dnipro City Council - PPDS; Dept of Chemotherapy
Dnipropetrovsk, Katerynoslav Governorate, 49102, Ukraine
Uzhgorod Central City Clinical Hospital
Uzhhorod, Katerynoslav Governorate, 88000, Ukraine
MNPE Zaporizhzhia Regional Antitumor Center ZRC
Zaporizhzhia, Katerynoslav Governorate, 69040, Ukraine
Communal Non profit Enterprise Regional Center of Oncology; Oncosurgical dept of thoracic organs
Kharkiv, Kharkiv Governorate, 61070, Ukraine
MNPE Transcarpathian Antitumor Center of the Transcarpathian Regional Council; Chemotherapy Dept
Uzhhorod, Kherson Governorate, 88014, Ukraine
Municipal Institution SubCarpathian Clinical Oncological Centre; Surgical department#2
Ivano-Frankivsk, KIEV Governorate, 76018, Ukraine
Communal Nonprofit Enterprise Podilsky Regional Center Of Oncology OfTheVinnytsia Regional Council
Vinnytsia, KIEV Governorate, 21029, Ukraine
SI Institute of Medical Radiology n.a. S.P. Hryhoriev of NAMS of Ukraine
Kharkiv, 61024, Ukraine
ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department
Kryvyi Rih, 50048, Ukraine
Kyiv City Clinical Oncological Center
Kyiv, 03115, Ukraine
Poltava Regional Clinical Oncology Dispensary of Poltava Regional Council; Thoracic department
Poltava, 36011, Ukraine
Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary
Sumy, 40005, Ukraine
Related Publications (9)
Zhou C, Dong X, Chen G, Wang Z, Wu X, Yao Y, Zhang Y, Cheng Y, Pan H, Zhang X, Cui J, Wang L, Chen X, Li X, Wang Z, Wang Q, He J, Wang M, Yan I, Qian L, Xu M, Huang X, Sun C, Cai J, Wu Q, Ballinger M, Kaul M, Srivastava MK. Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial. Nat Med. 2025 Jul;31(7):2375-2384. doi: 10.1038/s41591-025-03658-y. Epub 2025 May 16.
PMID: 40379995DERIVEDMang A, Zou W, Rolny V, Reck M, Cigoianu D, Schulze K, Holdenrieder S, Socinski MA, Shames DS, Wehnl B, Patil NS. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150. Tumour Biol. 2024;46(s1):S177-S190. doi: 10.3233/TUB-230001.
PMID: 37545290DERIVEDSocinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M, Finley GG, Kaul MD, Yu W, Paranthaman N, Bara I, West HJ. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncol. 2023 Apr 1;9(4):527-535. doi: 10.1001/jamaoncol.2022.7711.
PMID: 36795388DERIVEDTon TGN, Pal N, Trinh H, Mahrus S, Bretscher MT, Machado RJM, Sadetsky N, Chaudhary N, Lu MW, Riely GJ. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data. Clin Cancer Res. 2022 Jul 1;28(13):2844-2853. doi: 10.1158/1078-0432.CCR-22-0471.
PMID: 35511917DERIVEDNogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, Mok TSK, Finley G, Aerts JG, Orlandi F, Moro-Sibilot D, Jotte RM, Stroyakovskiy D, Villaruz LC, Rodriguez-Abreu D, Wan-Teck Lim D, Merritt D, Coleman S, Lee A, Shankar G, Yu W, Bara I, Nishio M. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. J Thorac Oncol. 2022 Feb;17(2):309-323. doi: 10.1016/j.jtho.2021.09.014. Epub 2021 Oct 7.
PMID: 34626838DERIVEDSocinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kong S, Lee A, Coleman S, Zou W, McCleland M, Shankar G, Reck M. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol. 2021 Nov;16(11):1909-1924. doi: 10.1016/j.jtho.2021.07.009. Epub 2021 Jul 24.
PMID: 34311108DERIVEDReck M, Wehler T, Orlandi F, Nogami N, Barone C, Moro-Sibilot D, Shtivelband M, Gonzalez Larriba JL, Rothenstein J, Fruh M, Yu W, Deng Y, Coleman S, Shankar G, Patel H, Kelsch C, Lee A, Piault E, Socinski MA. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 Aug 1;38(22):2530-2542. doi: 10.1200/JCO.19.03158. Epub 2020 May 27.
PMID: 32459597DERIVEDReck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.
PMID: 30922878DERIVEDSocinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
PMID: 29863955DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Medical Communications
- Organization
- Hoffmann-La Roche
Study Officials
- STUDY DIRECTOR
Clinical Trials
Hoffmann-La Roche
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 12, 2015
First Posted
February 19, 2015
Study Start
March 31, 2015
Primary Completion
September 13, 2019
Study Completion
December 7, 2020
Last Updated
September 23, 2021
Results First Posted
October 27, 2020
Record last verified: 2021-08